IRadimed Corporation announced its financial guidance for the full year 2026, projecting revenue in the range of $91.0 million to $96.0 million. The company expects GAAP diluted earnings per share to be between $1.90 and $2.05, and non-GAAP diluted earnings per share between $2.06 and $2.21. For the first quarter of 2026, IRadimed anticipates revenue between $21.0 million and $22.0 million, with GAAP diluted earnings per share ranging from $0.39 to $0.43, and non-GAAP diluted earnings per share between $0.44 and $0.48. The company also announced an increase in its regular quarterly cash dividend to $0.20 per share, up from $0.17 per share, reflecting confidence in its business outlook.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IRadimed Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9651592-en) on February 10, 2026, and is solely responsible for the information contained therein.